HDAC1 and plasma cell myeloma: Chidamide selectively binds to and inhibits HDAC1, 2, 3, and 10, proving effective as an anti-tumor agent in various cancers, including multiple myeloma, non-small cell lung cancer, and breast cancer [10, 25, 26].